Friday 6-13-2014 Alnylam Pharmaceuticals (ALNY) $ALNY opened at 67.82 hitting the high price of 68.40 and a day low of 66.08 with a total volume of 476,261. ALNY had a previous close of 67.74 and has been seeing an average volume of 848,355.
Overall Average: 64% Buy
Recent stock forum discussions about ALNY http://investorshangout.com/search?q=ALNY&...mp;yt0=Go!
Alnylam Announces United States Patent and Trademark Office (USPTO) Issues Patent Covering RNAi Therapeutics for the Treatment of Hepatitis B Virus (HBV) Infection
Business Wire - Thu Jun 12, 7:01AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that the United States Patent and Trademark Office (USPTO) has issued a new patent (U.S. patent no. 8,618,277, or "'277 patent"
in the company's McSwiggen patent estate. The McSwiggen patent estate broadly describes chemical modifications of RNAi therapeutics needed to achieve "drug-like" properties in siRNA, the molecules that mediate RNAi. Specifically, the '277 patent includes claims that the company believes are critical for the development of RNAi therapeutics for the treatment of hepatitis B virus (HBV) infection. This patent is held exclusively by Alnylam and is not licensed to any third parties. The McSwiggen patent estate comprises a core component of Alnylam's overall intellectual property (IP) estate for the advancement of RNAi therapeutics, and was recently obtained through the company's acquisition of Sirna Therapeutics from Merck. (full story)
Trial Results, Patient Enrollment, and Strategic Collaborations - Analyst Notes on Alnylam, Celldex, Keryx, Spectrum and MacroGenics
PR Newswire - Thu Jun 12, 4:20AM CDT
Today, Analysts Review released its analysts' notes regarding Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), Celldex Therapeutics, Inc. (NASDAQ: CLDX), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) and MacroGenics, Inc. (NASDAQ: MGNX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3634-100free. (full story)
Uptrend Call Working As Alnylam Pharmaceuticals Stock Rises 15.1% (ALNY)
Comtex SmarTrend(R) - Tue Jun 10, 9:10AM CDT
SmarTrend identified an Uptrend for Alnylam Pharmaceuticals (NASDAQ:ALNY) on May 13th, 2014 at $58.19. In approximately 4 weeks, Alnylam Pharmaceuticals has returned 15.13% as of today's recent price of $66.99. (full story)
Look for Shares of Alnylam Pharmaceuticals to Potentially Pullback after Yesterday's 7.53% Rise
Comtex SmarTrend(R) - Mon Jun 09, 5:04PM CDT
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $61.26 to a high of $66.86. Yesterday, the shares gained 7.5%, which took the trading range above the 3-day high of $61.38 on volume of 1.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. (full story)
RXi Pharma Advances sd-rxRNA Platform with Key Patent
ACCESSWIRE - Mon Jun 09, 9:04AM CDT
WHITEFISH, MT / June 9th , 2014 / RNA therapeutics have been growing in popularity over the past couple years with the FDA approval of ISIS Pharmaceuticals' (NASDAQ: ISIS) and Sanofi SA's (NYSE: SNY) Kynamro(R) as the first antisense drug to reach the market and Alnylam Pharmaceuticals' (NASDAQ: ALNY) successes in late-stage clinical trials utilizing RNA interference ("RNAi" in its so-called 5×15 clinical pipeline. (full story)
Alnylam Presents New Pre-Clinical Data with Development Candidate for ALN-CC5, a Subcutaneously Administered RNAi Therapeutic Targeting Complement Component C5 in Development for the Treatment of Complement-Mediated Diseases
Business Wire - Mon Jun 09, 7:01AM CDT
--- RNAi-Mediated Knockdown of C5 Shown to be as Effective as Anti-C5 Monoclonal Antibody in Reducing Clinical Disease Activity in Mouse Arthritis Model - (full story)
Alnylam to Webcast Presentation at Goldman Sachs 35th Annual Global Healthcare Conference
Business Wire - Wed Jun 04, 3:00PM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the Goldman Sachs 35th Annual Global Healthcare Conference on Wednesday, June 11, 2014 at 10:40 a.m. PT (1:40 p.m. ET) at the Terranea Resort in Rancho Palos Verdes, Calif. (full story)
Pre-clinical Trial Results, Expanded Studies, Preliminary Data Release, and Leadership Appointments - Analyst Notes on Alnylam, BioCryst, Puma Biotechnology, Intrexon and NW Bio
PR Newswire - Fri May 30, 4:40AM CDT
Today, Analysts Review released its analysts' notes regarding Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX), Puma Biotechnology, Inc. (NYSE: PBYI), Intrexon Corporation (NYSE: XON) and Northwest Biotherapeutics, Inc. (NASDAQ: NWBO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3120-100free. (full story)
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) to Ring The NASDAQ Stock Market Opening Bell
GlobeNewswire - Thu May 29, 9:00AM CDT
What: (full story)
Biotech 101: RNA Drugs
Brian Orelli, The Motley Fool - Motley Fool - Tue May 27, 5:00PM CDT
Disease-causing proteins can be inhibited by small-molecule drugs or by antibody drugs that bind to the protein, but there's a third class of drugs being developed that prevents the protein from being produced in the first place. They target mRNAs,... (full story)
Today's Dead Cat Bounce Stock: Alnylam Pharmaceuticals (ALNY)
at The Street - Wed May 21, 9:01AM CDT
Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a "dead cat bounce" (down big yesterday but up big today) candidate (full story)
Alnylam and Collaborators Publish Pre-Clinical Results with ALN-AS1, an RNAi Therapeutic Targeting Aminolevulinic Acid Synthase-1 (ALAS-1) for the Treatment of Hepatic Porphyrias, in the Proceedings of the National Academy of Sciences
Business Wire - Wed May 21, 7:01AM CDT
--- RNAi Therapeutics Targeting ALAS-1 Completely Block Production of Toxic Heme Biosynthesis Intermediates that Cause Symptoms and Disease Pathology - (full story)
Alnylam Pharmaceuticals Earnings In Retrospect: Up 14.0% in the Last 11 Days (ALNY)
Comtex SmarTrend(R) - Mon May 19, 1:02PM CDT
11 days ago, on May 8th, 2014, Alnylam Pharmaceuticals (NASDAQ:ALNY) reported its earnings. Analysts, on average, expected a loss of $0.58 per share on sales of $10.8 million. Alnylam Pharmaceuticals actually reported a loss of $0.39 per share on sales of $8.3 million, beating EPS estimates by $0.19 and missing revenue estimates by $2.5 million. Since the company's report, shares of Alnylam Pharmaceuticals have risen from $50.26 to $57.30, representing a gain of 14.0% in the past 11 days. (full story)
Alnylam: The Best Hepatitis B Play?
Todd Campbell, The Motley Fool - Motley Fool - Wed May 14, 10:05PM CDT
Alnylam shares jumped this week after reporting that it would actively advance an RNAi program for the treatment of chronic hepatitis B. Up to 400 million people suffer from chronic hepatitis B worldwide and, currently, there's no cure. The sheer... (full story)
Clinical Study Results, Upcoming Events, and Financial Updates - Analyst Notes on Amgen, Insys, Alnylam, Seattle Genetics and Emergent BioSolutions
PR Newswire - Wed May 14, 7:50AM CDT
Today, Analysts Review released its analysts' notes regarding Amgen, Inc. (NASDAQ: AMGN), Insys Therapeutics, Inc. (NASDAQ: INSY), Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), Seattle Genetics, Inc. (NASDAQ: SGEN) and Emergent BioSolutions Inc. (NYSE: EBS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2424-100free. (full story)
Alnylam Pharmaceuticals, Inc. Managing Multiple Irons In The Fire
Stephen D., Simpson,, The Motley Fool - Motley Fool - Tue May 13, 10:46AM CDT
Not only has the bloom left the rose of the biotech boom, investors have started plucking off the petals too. That has led to bowel-clenching declines for many biotechs, including Alnylam Pharmaceuticals . While the market is going to do what it's... (full story)
21.2% Return Seen to Date on SmarTrend Alnylam Pharmaceuticals Call (ALNY)
Comtex SmarTrend(R) - Tue May 13, 9:42AM CDT
SmarTrend identified a Downtrend for Alnylam Pharmaceuticals (NASDAQ:ALNY) on March 7th, 2014 at $73.88. In approximately 2 months, Alnylam Pharmaceuticals has returned 21.17% as of today's recent price of $58.24. (full story)
Biotech Stocks Technical Data -- Research on Alnylam Pharma, Regeneron Pharma, Cel-Sci, and Synta Pharma
PR Newswire - Tue May 13, 9:15AM CDT
On Monday, May 12, 2014, the NASDAQ Composite ended at 4,143.86, up 1.77%, the Dow Jones Industrial Average finished the day 0.68% higher at 16,695.47, and the S&P 500 closed at 1,896.65, up 0.97%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 675.29, up 1.04%, and the index has advanced 4.74% in the last one month. Investor-Edge has initiated coverage on the following equities: Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Cel-Sci Corporation (NYSE MKT: CVM) and Synta Pharmaceuticals Corporation (NASDAQ: SNTA). Free technical research on ALNY, REGN, CVM and SNTA can be downloaded upon signing up at: (full story)
Alnylam Reports Initial Positive Top-Line Data from Phase 1 Clinical Trial with ALN-AT3, an RNAi Therapeutic Targeting Antithrombin (AT) in Development for the Treatment of Hemophilia and Rare Bleeding Disorders (RBD)
Business Wire - Tue May 13, 7:00AM CDT
--- Results Demonstrate a Greater than 50-Fold Potency Improvement for Enhanced Stabilization Chemistry (ESC)-GalNAc-siRNA Conjugates in Humans, Representing an Unprecedented Advance in Delivery of RNAi Therapeutics with Subcutaneous Dose Administration - (full story)
Alnylam Pharma
at Investor's Business Daily - Mon May 12, 5:42PM CDT
Alnylam Pharma (ALNY), a Cambridge, Mass.-based biotech, said it has added a new program to its pipeline: ALN-HBV, for treatment of hepatitis-B virus, which affects an estimated 400 mil globally. The program resulted from Alnylam's acquisition of... (full story)
Overall Average: 64% Buy
Recent stock forum discussions about ALNY http://investorshangout.com/search?q=ALNY&...mp;yt0=Go!
Alnylam Announces United States Patent and Trademark Office (USPTO) Issues Patent Covering RNAi Therapeutics for the Treatment of Hepatitis B Virus (HBV) Infection
Business Wire - Thu Jun 12, 7:01AM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that the United States Patent and Trademark Office (USPTO) has issued a new patent (U.S. patent no. 8,618,277, or "'277 patent"
in the company's McSwiggen patent estate. The McSwiggen patent estate broadly describes chemical modifications of RNAi therapeutics needed to achieve "drug-like" properties in siRNA, the molecules that mediate RNAi. Specifically, the '277 patent includes claims that the company believes are critical for the development of RNAi therapeutics for the treatment of hepatitis B virus (HBV) infection. This patent is held exclusively by Alnylam and is not licensed to any third parties. The McSwiggen patent estate comprises a core component of Alnylam's overall intellectual property (IP) estate for the advancement of RNAi therapeutics, and was recently obtained through the company's acquisition of Sirna Therapeutics from Merck. (full story) Trial Results, Patient Enrollment, and Strategic Collaborations - Analyst Notes on Alnylam, Celldex, Keryx, Spectrum and MacroGenics
PR Newswire - Thu Jun 12, 4:20AM CDT
Today, Analysts Review released its analysts' notes regarding Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), Celldex Therapeutics, Inc. (NASDAQ: CLDX), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) and MacroGenics, Inc. (NASDAQ: MGNX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3634-100free. (full story)
Uptrend Call Working As Alnylam Pharmaceuticals Stock Rises 15.1% (ALNY)
Comtex SmarTrend(R) - Tue Jun 10, 9:10AM CDT
SmarTrend identified an Uptrend for Alnylam Pharmaceuticals (NASDAQ:ALNY) on May 13th, 2014 at $58.19. In approximately 4 weeks, Alnylam Pharmaceuticals has returned 15.13% as of today's recent price of $66.99. (full story)
Look for Shares of Alnylam Pharmaceuticals to Potentially Pullback after Yesterday's 7.53% Rise
Comtex SmarTrend(R) - Mon Jun 09, 5:04PM CDT
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded in a range yesterday that spanned from a low of $61.26 to a high of $66.86. Yesterday, the shares gained 7.5%, which took the trading range above the 3-day high of $61.38 on volume of 1.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. (full story)
RXi Pharma Advances sd-rxRNA Platform with Key Patent
ACCESSWIRE - Mon Jun 09, 9:04AM CDT
WHITEFISH, MT / June 9th , 2014 / RNA therapeutics have been growing in popularity over the past couple years with the FDA approval of ISIS Pharmaceuticals' (NASDAQ: ISIS) and Sanofi SA's (NYSE: SNY) Kynamro(R) as the first antisense drug to reach the market and Alnylam Pharmaceuticals' (NASDAQ: ALNY) successes in late-stage clinical trials utilizing RNA interference ("RNAi"
in its so-called 5×15 clinical pipeline. (full story) Alnylam Presents New Pre-Clinical Data with Development Candidate for ALN-CC5, a Subcutaneously Administered RNAi Therapeutic Targeting Complement Component C5 in Development for the Treatment of Complement-Mediated Diseases
Business Wire - Mon Jun 09, 7:01AM CDT
--- RNAi-Mediated Knockdown of C5 Shown to be as Effective as Anti-C5 Monoclonal Antibody in Reducing Clinical Disease Activity in Mouse Arthritis Model - (full story)
Alnylam to Webcast Presentation at Goldman Sachs 35th Annual Global Healthcare Conference
Business Wire - Wed Jun 04, 3:00PM CDT
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the Goldman Sachs 35th Annual Global Healthcare Conference on Wednesday, June 11, 2014 at 10:40 a.m. PT (1:40 p.m. ET) at the Terranea Resort in Rancho Palos Verdes, Calif. (full story)
Pre-clinical Trial Results, Expanded Studies, Preliminary Data Release, and Leadership Appointments - Analyst Notes on Alnylam, BioCryst, Puma Biotechnology, Intrexon and NW Bio
PR Newswire - Fri May 30, 4:40AM CDT
Today, Analysts Review released its analysts' notes regarding Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX), Puma Biotechnology, Inc. (NYSE: PBYI), Intrexon Corporation (NYSE: XON) and Northwest Biotherapeutics, Inc. (NASDAQ: NWBO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3120-100free. (full story)
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) to Ring The NASDAQ Stock Market Opening Bell
GlobeNewswire - Thu May 29, 9:00AM CDT
What: (full story)
Biotech 101: RNA Drugs
Brian Orelli, The Motley Fool - Motley Fool - Tue May 27, 5:00PM CDT
Disease-causing proteins can be inhibited by small-molecule drugs or by antibody drugs that bind to the protein, but there's a third class of drugs being developed that prevents the protein from being produced in the first place. They target mRNAs,... (full story)
Today's Dead Cat Bounce Stock: Alnylam Pharmaceuticals (ALNY)
at The Street - Wed May 21, 9:01AM CDT
Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a "dead cat bounce" (down big yesterday but up big today) candidate (full story)
Alnylam and Collaborators Publish Pre-Clinical Results with ALN-AS1, an RNAi Therapeutic Targeting Aminolevulinic Acid Synthase-1 (ALAS-1) for the Treatment of Hepatic Porphyrias, in the Proceedings of the National Academy of Sciences
Business Wire - Wed May 21, 7:01AM CDT
--- RNAi Therapeutics Targeting ALAS-1 Completely Block Production of Toxic Heme Biosynthesis Intermediates that Cause Symptoms and Disease Pathology - (full story)
Alnylam Pharmaceuticals Earnings In Retrospect: Up 14.0% in the Last 11 Days (ALNY)
Comtex SmarTrend(R) - Mon May 19, 1:02PM CDT
11 days ago, on May 8th, 2014, Alnylam Pharmaceuticals (NASDAQ:ALNY) reported its earnings. Analysts, on average, expected a loss of $0.58 per share on sales of $10.8 million. Alnylam Pharmaceuticals actually reported a loss of $0.39 per share on sales of $8.3 million, beating EPS estimates by $0.19 and missing revenue estimates by $2.5 million. Since the company's report, shares of Alnylam Pharmaceuticals have risen from $50.26 to $57.30, representing a gain of 14.0% in the past 11 days. (full story)
Alnylam: The Best Hepatitis B Play?
Todd Campbell, The Motley Fool - Motley Fool - Wed May 14, 10:05PM CDT
Alnylam shares jumped this week after reporting that it would actively advance an RNAi program for the treatment of chronic hepatitis B. Up to 400 million people suffer from chronic hepatitis B worldwide and, currently, there's no cure. The sheer... (full story)
Clinical Study Results, Upcoming Events, and Financial Updates - Analyst Notes on Amgen, Insys, Alnylam, Seattle Genetics and Emergent BioSolutions
PR Newswire - Wed May 14, 7:50AM CDT
Today, Analysts Review released its analysts' notes regarding Amgen, Inc. (NASDAQ: AMGN), Insys Therapeutics, Inc. (NASDAQ: INSY), Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), Seattle Genetics, Inc. (NASDAQ: SGEN) and Emergent BioSolutions Inc. (NYSE: EBS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2424-100free. (full story)
Alnylam Pharmaceuticals, Inc. Managing Multiple Irons In The Fire
Stephen D., Simpson,, The Motley Fool - Motley Fool - Tue May 13, 10:46AM CDT
Not only has the bloom left the rose of the biotech boom, investors have started plucking off the petals too. That has led to bowel-clenching declines for many biotechs, including Alnylam Pharmaceuticals . While the market is going to do what it's... (full story)
21.2% Return Seen to Date on SmarTrend Alnylam Pharmaceuticals Call (ALNY)
Comtex SmarTrend(R) - Tue May 13, 9:42AM CDT
SmarTrend identified a Downtrend for Alnylam Pharmaceuticals (NASDAQ:ALNY) on March 7th, 2014 at $73.88. In approximately 2 months, Alnylam Pharmaceuticals has returned 21.17% as of today's recent price of $58.24. (full story)
Biotech Stocks Technical Data -- Research on Alnylam Pharma, Regeneron Pharma, Cel-Sci, and Synta Pharma
PR Newswire - Tue May 13, 9:15AM CDT
On Monday, May 12, 2014, the NASDAQ Composite ended at 4,143.86, up 1.77%, the Dow Jones Industrial Average finished the day 0.68% higher at 16,695.47, and the S&P 500 closed at 1,896.65, up 0.97%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 675.29, up 1.04%, and the index has advanced 4.74% in the last one month. Investor-Edge has initiated coverage on the following equities: Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Cel-Sci Corporation (NYSE MKT: CVM) and Synta Pharmaceuticals Corporation (NASDAQ: SNTA). Free technical research on ALNY, REGN, CVM and SNTA can be downloaded upon signing up at: (full story)
Alnylam Reports Initial Positive Top-Line Data from Phase 1 Clinical Trial with ALN-AT3, an RNAi Therapeutic Targeting Antithrombin (AT) in Development for the Treatment of Hemophilia and Rare Bleeding Disorders (RBD)
Business Wire - Tue May 13, 7:00AM CDT
--- Results Demonstrate a Greater than 50-Fold Potency Improvement for Enhanced Stabilization Chemistry (ESC)-GalNAc-siRNA Conjugates in Humans, Representing an Unprecedented Advance in Delivery of RNAi Therapeutics with Subcutaneous Dose Administration - (full story)
Alnylam Pharma
at Investor's Business Daily - Mon May 12, 5:42PM CDT
Alnylam Pharma (ALNY), a Cambridge, Mass.-based biotech, said it has added a new program to its pipeline: ALN-HBV, for treatment of hepatitis-B virus, which affects an estimated 400 mil globally. The program resulted from Alnylam's acquisition of... (full story)
